Lupin gets USFDA nod to generic version of Prozac tablets

Published On 2019-04-16 04:15 GMT   |   Update On 2019-04-16 04:15 GMT

The company has received approval from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.


New Delhi: Drug maker Lupin Tuesday said it has received approval from the US health regulator to market Fluoxetine Tablets, used to treat the major depressive disorder, in the American market.


The company has received approval from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.


Also Read: Lupin receives USFDA approval for Testosterone Gel


The product is also indicated for the treatment of the obsessive-compulsive disorder, Bulimia Nervosa and panic disorder, it said.


Obsessive-compulsive disorder (OCD) is a mental disorder in which a person feels the need to perform certain routines repeatedly (called "compulsions"), or has certain thoughts repeatedly (called "obsessions"). The person is unable to control either the thoughts or activities for more than a short period of time.


Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.


Also Read: Lupin launches antidepressant drug Fluoxetine in the US market

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News